Compare Enphase Energy Inc (ENPH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs ResMed Inc. — how do they compare? Enphase Energy Inc trades at $32.81 (market cap $4.35B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 7.3× Enphase Energy Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and ResMed Inc. for 51 Days on average.
| ENPH | RMD | |
|---|---|---|
Market Cap | $4.35B | $31.89B |
Volume | 5,068,595 | 618,314 |
Sector | Energy | Health |
52-Week High | $72.33 | $275.96 |
52-Week Low | $26.12 | $182.82 |
Typical Hold Time | 72 Days | 51 Days |
Enterprise Value | $3.99B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.91, down 1.76% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations, with revenue declining from $2.3B in 2023 to $1.47B in 2025. Recent developments include IQ Meter Collar approval by 80 utilities and solid-state transformer advancements for AI data centers, providing potential growth catalysts amid challenging solar market conditions.
The outlook remains cautious with analyst consensus at Buy (41.82%) but near-term headwinds from high borrowing costs impacting solar financing. The stock trades at a P/E of 32.58, above sector averages, while maintaining solid gross margins of 46.95%. Key risks include solar industry volatility and execution challenges, though institutional ownership remains substantial with upside to the $43.18 consensus target.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
